RMP-A03 Ocular Suspension in Patients With Pterygium

• Status: Not yet recruiting
• Trial end date: 2024-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this clinical trial is to test the safety and efficacy of an ocular medication on the treatment of pterygium.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Suzhou Raymon Pharmaceuticals Company, Ltd.
• Collaborator: WuXi Clinical

Criteria

Inclusion Criteria:

• Must be at least 18 years old

• Diagnosis of pterygium with specified characteristics

• BCVA of 20/200 or better

• Willingness to attend all study visits and comply with the study procedures

Exclusion Criteria:

• Presence of ocular disease

• Double pterygium

• History of ocular surgery

• Presence of ocular trauma

• Use of any ocular medication

• Use of contact lens

• Allergy to any of the components of study drug

• Cannot properly administer study drug

• Clinically significant systemic disease that may place the subject at risk or confound study results

• Participation in an investigational study within 30 days prior to screening

• Female participants who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control (WOCBP).